This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
KUALA LUMPUR (July 19): CIMB Group Holdings Bhd's 94.11%-owned subsidiary CIMB Thai Bank PCL's net profit for the second quarter ended June 30, 2018 (2QFY18) was 46.38% lower to 191.23 million baht versus 356.64 million baht last year due to higher operating expenses coupled with an increase in provisions.
The FBM KLCI closed 15.79 points higher to 1,753.07, making it the best-performing index yesterday. The index has been on an upward trend since last week, after it fell to its 18-month low of 1,663.86 points on July 6.
1155 1023 4863 PBLOF MLYBY 6888 MLYNF AXXTF MYTEF 1295 CIMDF
The market rebounded last week on rebounds in Asian markets and the central bank’s move not to raise the overnight policy rate. However, the ringgit weakened and commodity prices continued to fall. Weakening ringgit caused foreign institutions to continue selling. Nevertheless, local market participants supported the market and the FBM KLCI increased 3.5% in a week to 1,721.93 points last Friday. The index continued to increase this week and closed at 1,737.
1023 PNADF 6888 AXXTF PNAGF 6033 CIMDF
KUALA LUMPUR (July 16): The FBM KLCI paused for a breather at midday break today, tracking regional markets as China’s economic growth showed a modest slowdown.
UPBMF 7113 TPGVF BATS 4162 2291 5202 7153 2089 5014 CIMDF TGLVY 1023 3204 4588 3026 5819 MYPRY
KUALA LUMPUR (July 13): The FBM KLCI rose 0.74% at midday break today, tracking gains at most regional markets, lifted by factors including key heavyweight index-linked stocks.
7052 UPBMF 5681 9679 2089 CIMDF 1023 3204 4863 5347 3867 0026 TNABY 6888 4723 AXXTF MYTEF TNABF GEBHF
IN May, Malayan Banking Bhd, the country’s largest financial services group, reached a new milestone, hitting RM100 billion in market capitalisation. It was an impressive, albeit brief, achievement as its market cap is now at RM97.83 billion, owing to skittish investor sentiment. Is it a good time to buy its shares, or those of CIMB, since both government-linked banks have taken a beating of late?
1155 1023 MLYBY MLYNF HYFXF HYFXY CIMDF
With the US-China tariff war kicking in last Friday, all eyes are now on US President Donald Trump, who has threatened to extend levies on all US$500 billion of goods imported from China, from US$34 billion currently. He also has several high-profile meetings in Europe this week.
7293 4065 7113 TPGVF 5014 CIMDF 6769 TGLVY 1023 3204 4863 5347 5148 5225 2127 TNABY 6888 MYPRY AXXTF MYTEF TNABF Q0F IHHHF
Top stocks: A man watches trading boards at a private stock market gallery in Kuala Lumpur. High on MIDF Research’s list of recommendations for the third quarter are Bermaz Auto Bhd and Malayan Banking Bhd, as well as Mah Sing Group Bhd and UOA Develeopment Bhd. — AP
1155 1023 MLYBY MLYNF 8583 CIMDF
KUALA LUMPUR (July 6): The FBM KLCI fell 0.77% at midday break as regional markets slumped, as U.S. tariffs against China took effect this afternoon.
PBLOF UPBMF 4065 6399 5681 1295 2089 7055 7154 5255 7277 CIMDF KLKBY 5139 1023 2445 0900 8613 0026 6888 2216 AXXTF
KUALA LUMPUR (July 6): The FBM KLCI fell 0.37% art mid-morning today, dragged by index-linked banking stocks against the backdrop of mixed regional markets.
MLYBY MLYNF UPBMF 4065 BATS 4162 2089 7055 7154 5255 CIMDF 1155 5139 1023 0900 0026 6888 5819 AXXTF
The FBM KLCI almost snapped a two-week decline last week after it rebounded last Friday from a mostly bearish week. The market went on bargain hunting on global markets’ cue. However, the market was still cautious as the ringgit continued to weaken and hence foreign institutions remained as net sellers. The FBM KLCI declined only 0.2% for the week to 1,691.5 points last Friday after rebounding from a low of 1,657.
1023 5347 6888 TNABY AXXTF TNABF 5168 HRGHY CIMDF
CIMB Group Holdings Bhd (July 2, RM5.41) Maintain buy with an unchanged target price of RM7.40: CIMB Group Holdings Bhd chairman Datuk Seri Nazir Razak, the face behind the country’s second largest lender, may leave the banking group. A source said Nazir had informed CIMB’s board of directors that he will not be seeking a re-election as the chairman of the banking group and will leave when his term finishes next August.
KUALA LUMPUR: Datuk Charon Wardini Mokhzani, formerly the executive director (ED) in the managing director’s office of Khazanah Nasional Bhd, has been appointed group managing director (MD) of Malaysian Industrial Development Finance Bhd (MIDF) effective immediately. This confirms a report by The Edge Malaysia weekly on April 16 that Charon was set to take the helm at the development financial institution, which is wholly-owned by Permodalan Nasional Bhd (PNB).
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET